Searching for New Potential Small-Molecule Modulators of Pro-Apoptotic Proteins Using the Yeast-Based Screening Assay by Verónica Sofia Leite Salazar e Costa
  
 
 
 
 
Verónica Sofia Leite Salazar e Costa 
 
 
 
SEARCHING FOR NEW POTENTIAL SMALL 
MOLECULE MODULATORS OF PRO-APOPTOTIC 
PROTEINS USING THE YEAST-BASED 
SCREENING ASSAY 
 
 
 
 
Dissertação do 2º Ciclo de Estudos Conducente ao Grau de Mestre em Química 
Farmacêutica 
 
Trabalho realizado sob a orientação da Professora Doutora Lucília Helena Ataíde 
Saraiva e coorientação da Professora Doutora Honorina Maria de Matos Cidade e 
Doutora Mariana Valencia C. Ferreira Leão 
 
 
July 2015 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DE ACORDO COM A LEGISLAÇÃO EM VIGOR, NÃO É PERMITIDA A REPRODUÇÃO  
DE QUALQUER PARTE DESTA TESE.  
iii 
 
ACKNOWLEDGEMENTS 
“Science is a way of life. Science is a perspective. Science is the process that takes us from 
confusion to understanding in a manner that's precise, predictive and reliable - a 
transformation, for those lucky enough to experience it, that is empowering and emotional.” 
Brian Greene 
 
First, I would like to thank to my supervisor Professor Lucília Saraiva for opening the 
doors of her laboratory and allow me to join her fantastic research group. Thank you for the 
opportunity, accompaniment, patient and transmitted knowledge. No doubt that she is a 
person for whom I have great admiration for everything she has conquered so far.  
I would also like to thank my co-supervisors for the all the support and enormous 
knowledge given to me in this period. To Mariana for helping me in my first steps as a 
researcher, for having taught me the bases and giving me precious tips. To Professor 
Honorina for all the words of encouragement and the huge sense of peace that she pours. 
To my dear research group: Ana Sara, Sara Gomes, Joana Soares, Liliana 
Raimundo, Helena Ramos, Mariana Leão and Cláudia Bessa, a huge thank from my heart. 
Without you, this would not have been possible. Thanks for all the good advice, support, 
willingness and transmitted knowledge. They were always by my side and made me grow 
as a person. Each of you has taught me something that will be precious in my life's journey. 
I would particularly like to thank Cláudia, you taught me a lot during this experience, always 
with great care and professionalism. Much of what I’ve learned, I’ve learned with you. 
I cannot forget the support given by the laboratory assistant, Cristina, always ready 
to help me, happy and expeditious. I will not forget what you did for me. But overall, thanks 
to all the other assistants, Nuno and Fernanda. They are equally spectacular. 
I would also like to thank to Professor Madalena Pinto, as well as, Professor 
Honorina Cidade, Professor Emília, Professor Carla and Professor Carlos Afonso. Thank 
you for making this master’s degree excellent. I am sure it will open several doors in the 
near future. 
My biggest acknowledgement goes to my parents. Everything I do is in order to 
make you proud. Thank you for all the efforts you do for me, you are the best persons in 
the world. In particularly to my mother which is the best mother ever. Thank you very much 
for all the support, friendship, for all the laughs, for being by my side making this process 
easier, for all the love in general. One day I want to be like you. I hope someday to be able 
to return what you have done for me. 
 
iv 
 
I cannot forget to thank to my boyfriend André. Your support was crucial during these 
time. You always believed in my value and also made me believe too. I hope you will be 
part of my life forever, contending together to have success in our lives. You were always 
on my side in the worst and best moments making me smile. 
To my friends Letícia and Agostinho, thank you very much for sharing this 
experience with me. Your support and friendship was unconditional. But overall, thanks to 
all my colleagues and masters degree’s friends. I wish you plenty of success in your life. 
 
 
This work was developed in the Laboratório de Microbiologia, Departamento de 
Ciências Biológicas, Faculdade de Farmácia da Universidade do Porto and in Centro de 
Química Medicinal da Universidade do Porto – CEQUIMED-UP, Laboratório de Química 
Orgânica e Farmacêutica, Departamento de Ciências Químicas, Faculdade de Farmácia 
da Universidade do Porto. This research was partially supported by the Strategic Funding 
UID/Multi/04378/2013 and UID/Multi/04423/2013 through FCT - Foundation for Science 
and Technology, FEDER funds through the Operational Programme for Competitiveness 
Factors – COMPETE and European Regional Development Fund (ERDF), in the framework 
of the programme PT2020 and the Project Pest-OE/SAU/UI4040/2014 and UCIBIO-Pest-
C/EQB/LA0006/2013. 
 
 
   
     
 
 
 
v 
 
RESUMO 
 
A pesquisa de novas terapias contra o cancro tem vindo a assentar na promoção 
da apoptose, bem como, em formas de ultrapassar a resistência a este processo nas 
células tumorais. As caspases são uma família de proteases com função crucial na 
apoptose. As caspases-3, -6 e -7 encontram-se na fase executora da apoptose, 
armazenadas como procaspases que uma vez ativadas por proteólise clivam um grande 
número de substratos, resultando na apoptose. Assim sendo, a pesquisa de ativadores 
destas procaspases merecem especial atenção na descoberta de novos potenciais 
fármacos anticancerígenos. Num trabalho anterior realizado pelo nosso grupo, utilizando o 
modelo de pesquisa da levedura Saccharomyces cerevisiae expressando as caspases-3, 
-6 e -7 humanas, levou à identificação de dois compostos ativadores da caspase-7: 5,6-
dihydroxy-7-prenyloxyflavone (1a) and 3-hydroxy-7-geranyloxyflavone (2a). Estes 
resultados incitaram à realização da presente tese com o objetivo de descobrir novos 
ativadores das caspases-3, -6 e -7. Para isso, foram sintetizados análogos dos compostos 
1a e 2a, e a sua atividade foi avaliada usando o modelo de levedura desenvolvido no 
trabalho anterior. Desta forma, foram identificados três potenciais ativadores da caspase-
7: 7-(allyloxy)-5,6-dihydroxy-2-phenyl-4H-chromen-4-one (S1), 6-dihydroxy-2-phenyl-7-
propoxy-4H-chromen-4-one (S2) and 5,6-dihydroxy-7-(isopentyloxy)-2-phenyl-4H-
chromen-4-one (S3). 
A proteína cinase C (PKC) é uma família de cinases de serina/treonina envolvidas 
na regulação da proliferação e morte celular, desempenhando assim um papel crucial no 
processo de carcinogénese. Desta forma, esta família representa um alvo promissor na 
terapia anticancerígena. Com base nisto, num trabalho prévio foi desenvolvido um ensaio 
de levedura para a pesquisa de moduladores isoforma-seletivos de PKCs. Utilizando este 
modelo foi identificado o composto C4 como potencial ativador da PKCδ. Baseado nisto, 
na presente tese foi analisada a atividade antitumoral in vitro deste composto em linhas 
celulares HCT116 do adenocarcinoma do cólon. O composto C4 exibiu uma potente 
inibição do crescimento nas células tumorais associada com a indução da apoptose.  
Concluindo, foram identificados novos reguladores farmacológicos de proteínas 
pro-apoptóticas no presente trabalho, representando uma alternativa de estratégia 
personalizada no tratamento do cancro. Presentemente, mais trabalho está a decorrer de 
forma a confirmar o mecanismo de ação molecular dos mesmos em células tumorais 
humanas.  
 
Palavras-chave: Cancro; Descoberta de novos fármacos; Modelo de pesquisa na 
levedura; Família de proteínas Caspases; Família de proteínas PKC. 
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ABSTRACT 
 
The search for new therapies against cancer has been focused on devising ways to 
overcome resistance and to trigger apoptosis in tumour cells. Caspases are a family of 
proteases with a crucial role in apoptosis. Caspases-3, -6 and -7 are at the core of the 
execution phase of apoptosis, stored as procaspases that once activated cleave a large set 
of substrates, ultimately resulting in the hallmarks of apoptosis. Therefore, the search for 
activators of these procaspases has deserved particular attention in the field of anticancer 
drug discovery.  
In a previous work from our group, the use of a yeast screening assay, based on the 
heterologous expression of human caspases-3 or -7 in the yeast Saccharomyces 
cerevisiae, led to the identification of two prenylated flavonoids as potential activators of 
caspase-7: 5,6-dihydroxy-7-prenyloxyflavone (1a) and 3-hydroxy-7-geranyloxyflavone (2a). 
These results prompted us to the present work aiming to discover new activators of 
caspases-3, -6 and -7. For that, analogues of flavonoids 1a and 2a were synthesised, and 
their activities on these proteins were evaluated, using the previously developed yeast-
based screening assay. Three new potential selective activators of caspase-7 were 
identified: 7-(allyloxy)-5,6-dihydroxy-2-phenyl-4H-chromen-4-one (S1), 6-dihydroxy-2-
phenyl-7-propoxy-4H-chromen-4-one (S2) and 5,6-dihydroxy-7-(isopentyloxy)-2-phenyl-
4H-chromen-4-one (S3). 
 The protein kinase C (PKC) is a family of serine/threonine kinases involved in the 
regulation of cell proliferation and death, playing therefore a major role in the carcinogenesis 
process. Thus, this family represents a promising and appealing target in anticancer 
therapy. In this way, in a previous work, a yeast targeted screening assay was developed 
to search for PKC isoform-selective modulators. Using this yeast approach, the compound 
C4 was identified as a potential selective activator of PKCδ. Based on this, in the present 
dissertation, the in vitro antitumor activity of C4 was analysed in the human colon 
adenocarcinoma HCT116 cell lines. The tested compound exhibited a potent growth-
inhibitory activity in tumour cells, which was associated with apoptosis induction.    
In conclusion, in this dissertation, new potential pharmacological regulators of pro-
apoptotic proteins were identified. Further work is underway to confirm their molecular 
mechanism of action in human tumour cells. Despite that, the data emerged from the 
present work demonstrated that these compounds may represent an alternative strategy 
for personalized cancer treatment. 
 
Keywords: Cancer; Drug discovery; Yeast-based screening assays; Caspases family 
proteins; PKC family proteins. 
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1. PRINCIPLES ABOUT CANCER 
 
Cancer is a major public health problem worldwide, with approximately 14 million 
new cases and 8.2 million cancer related deaths in 20121. In fact, according to the World 
Health Organization, the number of new cases is expected to rise about 70% over the next 
2 decades. Thus, the discovery of new therapeutic agents against this severe pathology is 
of enormous interest and urgently required.  
Carcinogenesis is a multistep process reflecting a series of genetic and epigenetic 
alterations in normal human cells that drives their progressive transformation into highly 
malignant derivatives2. All cancers have many features in common at the molecular level. 
This suggests that the biochemical processes, including abnormalities in the genetic 
reading process leading to the development and progression of malignant transformation, 
follow a common pattern [reviewed in3].  
According to Hanahan and Weinberg (2000) there are six hallmarks of cancer, 
comprising six biological capabilities acquired during the multistep development of human 
tumours. They include sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis. Recently, in 2011, two emerging hallmarks were added to this list: 
the capability to reprogram the energy metabolism, in order to control the neoplasic 
transformation, and the capability of cancer cells to evade immunological destruction 
(Figure 1) [reviewed in4]. 
 
Sustaining proliferative signalling 
Tumour cells have the capacity to stimulate its own growth and to resist to inhibitory 
signals to stop it, while normal cells require external growth factors to grow and divide, and 
if one of these signs is absent, they stop growing. In tumour cells, the presence of these 
external growth factors is not necessary to multiply, because they can generate their own 
growth factors, or the receptors are themselves overexpressed [reviewed in5]. 
 
Resisting cell death 
Apoptosis is a form of programmed cell death that occurs in normal cells in response 
to cellular damages and is a crucial process for the maintenance of tissue homeostasis in 
multicellular organisms [reviewed in6]. Tumour cells are able to bypass this process. This 
cell death process is highly regulated by many proteins, such as the p53 tumour suppressor, 
caspases and Bcl-2 family members, among others. Any deregulation of this process lead 
to resisting cell death [reviewed in7]. 
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Figure 1 –The hallmarks of cancer acquired during the multistep development of human tumours lead to an 
uncontrolled growth. Apoptosis is required to control the development and progression of malignant 
transformation. 
 
Enabling replicative immortality/evading growth suppressors 
Normal cells can multiply about 60-70 doublings, and after this number of divisions 
they enter in senescence. Tumour cells, with damaged chromosomes, escape this limit, 
being capable of indefinite growth and division. This immortalization may be due to 
numerous processes, particularly, due to the disabling of retinoblastoma (pRB) and p53 
tumour suppressor protein, which allow tumour cells to continue doubling. The counting 
device for cell doublings is the telomere, which loses DNA at the tips of every chromosome 
during each cell cycle. Many tumours involve the upregulation of telomerase, the enzyme 
that maintains telomeres [reviewed in5]. 
 
Inducing angiogenesis 
Angiogenesis is the process by which new blood vessels are formed. Tumour cells 
initially do not have angiogenic ability, limiting their ability to expand. For instance, they 
must develop a blood supply in order to receive continual supply of oxygen and other 
nutrients. During tumorigenesis, the appropriate balance between proangiogenic and 
antiangiogenic molecules is lost [reviewed in8]. Tumour-angiogenesis therefore depends on 
tumour type, localization, growth, and stage of disease, and contributes to tumour growth, 
invasion, and metastasis [reviewed in9]. 
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Activating invasion and metastasis 
Tumour cells can spread to different parts of the body, in other words, they can 
metastasize. Metastatic cells must mimic normal cell-cell interactions, through cell-cell 
adhesion molecules (CAMs) and integrins. Integrins display substrate preferences, and 
changes in integrins are displayed by migrating cells. Matrix-degrading proteases are also 
necessary to facilitate invasion into stroma, across blood vessel walls, and through normal 
epithelial cell layers [reviewed in10]. 
 
Reprogramming energy metabolism 
In the presence of oxygen, normal cells process glucose into pyruvate via glycolysis 
in the cytosol, and thereafter to carbon dioxide in the mitochondria. In the absence of 
oxygen, glycolysis is favoured and relatively little pyruvate is dispatched to the oxygen-
consuming mitochondria. Tumour cells are able to reprogram their energy metabolism. 
Even in the presence of oxygen, tumour cells can reprogram their glucose metabolism, and 
thus their energy production, by limiting their energy metabolism largely to glycolysis 
[reviewed in4]. 
  
Evading immune destruction 
Cells and tissues are constantly monitored by an immune surveillance that is 
responsible for recognizing and eliminating the wide majority of tumour cells and nascent 
tumours. However, it seems that the solid tumours are able to avoid detection by the 
immune system or have been able to limit the extent of immune killing, evading 
immunological destruction, in particular by T and B lymphocytes, macrophages, and natural 
killer cells, avoiding eradication [reviewed in4]. 
 
1.1. APOPTOSIS 
 
Apoptosis is a type of programmed cell death that occurs when DNA damage is 
irreparable. This process is characterized by specific morphological and biochemical 
features, including blebbing, cell shrinkage, nuclear fragmentation, chromatin 
condensation, and chromosomal DNA fragmentation [reviewed in11]. The mechanisms of 
apoptosis are highly complex and sophisticated, involving an energy-dependent cascade of 
molecular events [reviewed in12]. 
There are two main apoptotic pathways: the extrinsic or death receptor pathway and the 
intrinsic or mitochondrial pathway (Figure 2) [reviewed in13]. 
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Figure 2 – The extrinsic and intrinsic pathways of apoptosis. Abbreviations: AIF - apoptosis inducing factor; 
Apaf-1 - apoptotic protease-activating factor 1; BID - BH3-interacting domain death agonist; tBID - truncated 
BID; Cyt. c - cytochrome c; DISC - death-inducing signalling complex; Endo G - endonuclease G; FADD - Fas-
associated protein with death domains; IAP - inhibitors of apoptosis family; MOMP - mitochondrial outer 
membrane permeabilization; Smac/DIABLO - second mitochondria-derived activator of caspases. 
 
The extrinsic pathway requires the activation of cell death receptors, namely tumour 
necrosis factor (TNF) superfamily, such as TNF, CD95 (Fas), and TNF-related apoptosis 
inducing ligand (TRAIL) receptors, found on the surface of the cell membranes, and their 
respective ligands transmitting the death signal from the surface to the intracellular 
signalling pathways. The activation of some receptors, as CD95 and TNF, leads to receptor 
clustering and intracellular recruitment of proteins such as the protein adaptor FADD (Fas-
associated protein with death domains). In turn, FADD recruits the initiator procaspase-8, 
forming the death-inducing signalling complex (DISC). The formation of this complex leads 
to the activation of procaspase-8, an initiator caspase. This activation induces the execution 
phase of apoptosis via the activation of the executioner procaspases-3, -6 and -7 or induces 
the cleavage of the BH3-interacting domain death agonist (BID), leading to the generation 
of a mitochondrion-permeabilizing fragment, the truncated BID (tBID) [reviewed in13-14]. 
On the other hand, the mitochondrial pathway is activated by stress signals such as 
DNA damage, oxidative stress, hypoxia or chemotherapeutic drugs. These external stimuli 
lead to modifications in the inner mitochondrial membrane permeability. These alterations 
induce changes at the mitochondrial outer membrane permeabilization (MOMP), loss of 
6 
 
mitochondrial transmembrane potential (Δѱm) and to the release of pro-apoptotic proteins 
such as cytochrome c (cyt c), the second mitochondria-derived activator of caspases 
(Smac/DIABLO), the apoptosis inducing factor (AIF) and the endonuclease G (Endo G) 
[reviewed in13]. 
After release into the cytoplasm, cyt c binds to the apoptotic protease-activating 
factor 1 (Apaf-1) and to procaspase-9, stimulating the apoptosome formation. In turns, the 
apoptosome activates procaspase-9, which in turn activates the executioner procaspases-
3, -6 and -7, resulting in an apoptotic cell death [reviewed in15]. Smac/DIABLO binds and 
inhibits several members of the inhibitor of apoptosis (IAP) family, preventing the IAPs from 
arresting the apoptotic process, thereby activating the executioner procaspases-3, -6, and 
-7, allowing apoptotic progression [reviewed in13]. 
In some models, the release of AIF and Endo G is a late event in apoptosis, which 
occurs once the cells are committed to die. Following the release of AIF and Endo G, these 
proteins are able to translocate to the nucleus, promoting DNA fragmentation through a 
caspase-independent manner [reviewed in14].The intrinsic pathway is mainly controlled by 
Bcl-2 family members, once they play a central role in the regulation of cyt c release from 
mitochondria. This family consists of anti-apoptotic members, such as Bcl-2 and Bcl-xL, and 
pro-apoptotic members, such as Bax, Bak and Bid. Bcl-2 and Bcl-xL are able to inhibit cyt 
c release by the protection of the membrane integrity through the interaction of these anti-
apoptotic proteins with mitochondrial proteins such as the adenine nucleotide translocase 
(ANT) or the voltage dependent anion channel (VDAC), thus preventing them from forming 
mitochondrial pores. On the other hand, Bax can homodimerize or heterodimerize with Bak 
or tBib, leading to the disruption of the mitochondrial membrane integrity through the 
formation of mitochondrial pores, with the subsequent cyt c release [reviewed in13]. 
The apoptotic process is essential for the maintenance of tissue homeostasis in 
multicellular organisms. It is well-known that the deregulation of this process has been 
implicated in numerous pathological conditions such as in cancer [reviewed in16]. In this 
way, the search for new anticancer therapies has been focused on devising ways to 
overcome increasing tumour resistance and to trigger apoptosis in tumour cells. It is clear 
that a number of anticancer drugs induce apoptosis in tumour cells. However, the problem 
is that some of these drugs usually induce cell death in normal cells as well. Therefore, the 
goal is to selectively modulate genes/proteins involved in apoptosis in tumour cells. In this 
way, understanding how those genes/proteins work reveals to be a crucial task for the 
development of more potent and effective compounds [reviewed in17]. 
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1.2. TARGET PROTEINS OF THE APOPTOTIC PATHWAY 
 
1.2.1. CASPASES 
 
It became evident that the cellular and biochemical features of apoptosis are a 
consequence of the cleavage of a subset of proteins by proteases of the caspase family 
[reviewed in18]. The central role in the regulation and in the execution of apoptotic cell death 
belongs to caspases. In fact, an inappropriate caspase activity can cause deficient cell 
death, potentially leading to carcinogenesis and other apoptotic-associated pathologies 
[reviewed in19]. 
Caspases are a conserved family of cysteine-dependent aspartate-specific proteases 
that are expressed in an inactive proenzyme form (zymogens). Structurally caspases 
consist of an N-terminal prodomain, followed by a large subunit with 20 kDa (p20) and a 
small subunit with 10 kDa (p10). The N-terminal prodomain contains structural motifs that 
belong to the death domain superfamily: the death effector domain (DED) and the caspase 
recruitment domain (CARD) [reviewed in20] (Figure 3). Depending on the structure and 
cellular functions, caspases are divided in inflammatory (Group I: caspases-1, -4, -5, -11, -
12 e -13) and apoptotic (caspases-2, -3, -6, -7, -8, -9 e -10). In addition, apoptotic caspases 
are divided in initiator caspases (Group II: -2, -8, -9 e -10) and effector caspases (Group III: 
-3, -6 e -7) (Figure 3) [reviewed in21]. 
 
 
 
Figure 3 – Caspase family structure. Three major groups of caspases are presented: group I: inflammatory 
caspases; group II: initiator caspases; group III: effector caspases. Caspases consist of a single chain 
constituted by three domains: N-terminal prodomain (DED and CARD), large (p20) and small (p10) catalytic 
subunits. Adapted from20. 
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In most cells, caspases are activated through proteolytic cleavage in specific 
asparagines residues (Asp-X). This results in the generation of mature caspases, allowing 
the initiation of a protease cascade that is implicated in the inflammatory process and in 
apoptosis [reviewed in22] (Figure 4). This strategy provides a control over the activity of 
caspases, in order to reduce the possibility of, inadvertently, they enter apoptosis [reviewed 
in23]. Initiator caspases are presented in cells as inert monomers, which require dimerization 
and inter-domain cleavage for their activation. In contrast, effector caspases present 
themselves as inactive dimers, requiring cleavage of its catalytic domain, leading to 
intermolecular rearrangements with consequent formation of enzymatically active dimer 
[reviewed in24]. 
 
 
Figure 4 – Scheme of caspase activation. Cleavage of the procaspase leads to the formation of mature caspase, 
which comprises the heterotetramer p202–p102 without the prodomain. Adapted from20. 
 
There are two pathways through which the caspase family proteases can be activated: 
one is the signal-induced death receptor-mediated pathway and the other is the stress-
induced, mitochondria-mediated pathway [reviewed in24]. This proteolytic cascade, in which 
one caspase can activate other caspases, amplifies the apoptotic signalling pathway, 
leading to a rapid cell death. Basically, caspases may be activated in response to different 
pro-death stimuli through the formation of activating complexes in the presence of adaptor 
proteins [reviewed in25]. 
The outcome of death receptor--mediated activation of caspase-8 depends of the cell 
type [reviewed in21]. In type I cells, procaspase-8 activation can directly activate 
downstream effector caspases (caspases-3, -6, -7) to promote DNA damage and apoptosis 
without requirement of the mitochondria dependent pathway. On type II cells, the apoptotic 
process is mostly controlled by Bcl-2 family members. Both caspase-8 and -2 can cleave 
and activate the pro-apoptotic Bcl-2 family protein. Indeed, Bax can homodimerize or 
heterodimerize with Bak or tBib, leading to the disruption of the mitochondrial membrane 
integrity, release of cyt c, and to the subsequent induction of the intrinsic apoptosis pathway. 
Once released, cyt c binds to Apaf-1, which recruits procaspase-9 to form the apoptosome. 
Subsequently, caspase-9 is activated and cleaves the effector caspases-3,-6 and -7, 
leading to the induction of apoptosis in a caspase-dependent manner [reviewed in26]. 
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Caspases activity can be suppressed by caspase inhibitor proteins, such as cowpox 
virus cytokine response modifier A (crmA), baculoviral p35/p49 and IAPS, a family of cellular 
proteins including, neuronal apoptosis inhibitory protein (NAIP), cellular IAP1 (cIAP1) and 
2 (cIAP2), X-linked IAP (XIAP), survivin, bruce, melanoma IAP (ML-IAP) and IAP-like 
protein 2 (ILP2) [reviewed in27]. 
Mutation in CASP genes is not frequent in human tumour cells. In fact, it is believed that 
the inactivation of individual caspases is not usually sufficient to prevent the progression of 
caspase cascade. However, the reduced expression of pro-apoptotic caspases has been 
reported in manifold cancers, as well as specific inactivating mutations have been reported 
in many tumour types and stages of malignant transformation [reviewed in21]. 
Despite of the enormous relevance of initiator caspases, in this dissertation a particular 
attention will be given to effector caspases. 
 
 
1.2.1.1. EFFECTOR CASPASES 
 
Caspases-3, -6 and -7 are at the core of the execution phase of apoptosis [reviewed 
in28]. Structurally these proteases are composed by large and small catalytic subunits, 
existing in the cells as inactive homodimers. The effector caspases are activated through 
proteolytic cleavage mediated by an initiator caspase [reviewed in19]. Once activated, 
besides to lead to cell death through cleavage of specific target proteins, the executioner 
caspases will be able to activate other effector caspases, leading to the generation of a 
feedback loop of caspase activation [reviewed in21]. 
 
Caspase-3 
Caspase-3 is encoded by the CASP3 gene located in chromosome 4q35.1 and is 
the most well-characterized effector caspase, since exerts a key role in both extrinsic and 
intrinsic apoptotic pathways. Caspase-3 has both distinct and overlapping roles with 
caspase-6 and -729. The divergent amino-terminal sequences between caspase-3 and -7 
appear to contribute to different modes of regulation30. In fact, Slee et al. (2001) performed 
a study where caspases-3, -6 and -7 were silenced in order to analyse the impact of the 
absence of these proteases on the execution phase of apoptosis. Indeed, the authors 
demonstrated that caspase-3 is a key component of the apoptotic process by participating 
in several events among this process, while caspase-6 and -7 exert more specialized 
roles31. 
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Many studies demonstrated that alterations in the CASP3 gene might promote 
human tumorigenesis, suggesting that caspase-3 may play a crucial role in cancer 
prevention. In fact, CASP3 polymorphism and their haplotypes help to define the individual’s 
genetic susceptibility to cancer development [reviewed in21]. This may happen since the 
CASP3 gene can give rise to an alternative splicing variant known as caspase-3s, which 
exert an anti-apoptotic function [reviewed in32].  
Additionally, distinct works have demonstrated that procaspase-3 is overexpressed 
in a variety of human tumours, namely, colon cancer33, lung cancer34, melanoma35, 
hepatoma36, breast cancer37, among others. 
 
Caspase-6 
Caspase-6 is encoded by the CASP6 gene located in chromosome 4q25. This 
executioner caspase are much more weakly apoptotic than caspase-3 and -738. 
Nevertheless, caspase-6 also cleaves a different set of cellular substrates39. The substrates 
of this effector caspase include PARP, lamin and procaspase-3. In fact, caspase-6 can 
activate procaspase-3 by a positive feedback pathway [reviewed in22]. 
The way how caspase-6 is activated is still controversial. In 2009, it has been 
reported that caspase-6 is activated only following activation of caspases-3 and -7 and thus 
is not activated directly by an initiator caspase29. However, in contrast, previous works 
showed that this caspase can be activated in the absence of caspase-3 and -740. More 
recently, it has been reported that, in vivo, caspase-6 can activate itself41. 
Expression of caspase-6 in gastric cancer is decreased, suggesting that loss of 
caspase-6 expression might be involved in the mechanism of gastric cancer development42. 
In fact, mutations in the CASP6 gene have been found in 2% of human cancers of colonic 
and gastric origin43. 
 
Caspase-7 
Caspase-7 is encoded by the CASP7 gene located in chromosome 10q25.3. This 
caspase shares many similarities with caspase-3. Both proteases are effector caspases 
and are substrates of initiator caspases in the extrinsic or intrinsic apoptotic pathways.  
Despite that, caspases-3 and -7 exhibit distinct activities in vivo [reviewed in32]. This may 
be due to the presence in caspase-7 of an inhibitor of apoptosis binding motif (IBM), which 
is absent in caspase-3, that appears to be more efficiently ubiquitinated by IAPs, leading to 
a more readily proteasomal degradation of caspase-7 compared to caspase-344. In fact, 
several substrates are specifically cleaved by caspase-7, such as cochaperone p23 
[reviewed in30a, 45]. 
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Mutations in the CASP7 gene affect the pathogenesis of some human solid cancers, 
since the function of caspase-7 is compromised [reviewed in21]. In fact, in the analysis of 
multiple types of cancer, developed in 2003, somatic mutations in CASP7 were detected in 
2% of colon and esophageal carcinomas and 3% in head/neck carcinomas46. 
 
 
1.2.1.1.1. SMALL MOLECULE ACTIVATORS OF CASPASES FAMILY 
 
The activation of effector caspases with small molecules could be important in the 
activation of these proteases and could have a direct impact on important physiological 
processes [reviewed in28]. Indeed, caspase activation can be particularly applied as an 
anticancer strategy by selective induction of apoptosis in cancer cells [reviewed in47]. Thus, 
the discovery of small molecule caspase activators has deserved particular relevance in the 
cancer field [reviewed in32]. However, to date, only few small molecule caspase activators 
have been reported  [reviewed in28, 47]. 
Putt et al. (2006) discovered the Procaspase-Activating Compound 1 (PAC-1) 
(Figure 5A) as the first small molecule caspase activator that induces apoptosis in cancer 
cells through the activation of procaspases-3 and -733. 
 
 
 
 
 
Figure 5 - Chemical structures of (A) PAC-1 which activates caspases-3 and -7, (B) M1541 which activates 
caspases-3 and -6 (C) M1541B, (D) WF-210 which activate caspase-3. 
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In fact, PAC-1 does not act by direct activation of executioner caspases, but through 
the zinc ion chelation, the more physiologically relevant metal in inhibiting procaspases 
activity (Figure 6)48. Despite that, some studies stated that PAC-1 is able to kill cerebellar 
granule neurons in vitro and causes neurotoxicity in vivo49. Therefore, these evidences led 
to intensive efforts in the development of novel procaspase activators with minimal side 
effects. 
 
 
 
Figure 6 – Mechanism of action of compound PAC-1. Adapted from33. 
 
In 2009, Wolan and colleagues verified that compound M1541 (Figure 5B) was able 
to induce apoptosis in the p53-deficient breast cancer cell line BT549. In this study, it was 
reported that M1541 can bypass initiator caspase activation and directly induce apoptosis 
in a caspase-3/-6-dependent manner without requiring apoptotic stimuli or upstream 
factor50. This can be a promising strategy in cancer therapy where apoptosis of cancer cells 
can be directly triggered, resulting in cell death [reviewed in28]. In the same study, it was 
reported a potent activator of procaspase-3, compound M1545B (Figure 5C), an analogue 
of M154150. Compound M1541B appears to activate procaspase-3 via a binding-induced 
shift in the on-off state equilibrium50, or trough formation of nanofibriles51. 
More recently, a novel procaspase-3 activator, WF-210, (Figure 5D) was 
discovered. WF-210 induces apoptosis in human leukemia cell lines HL-60 and U-937 by 
activating procaspase-3. This compound showed higher in vivo efficacy and safety 
characteristics compared with PAC-152. 
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1.2.2. PROTEIN KINASE C FAMILY PROTEINS 
 
The protein kinase C (PKC) is a family of serine/threonine kinases that are involved in 
relevant processes, including neoplastic transformation, carcinogenesis and tumour cell 
invasion. Hence, in these processes, the activity and expression of some of these kinases 
are altered. Therefore, they are potentially suitable targets for anticancer therapy [reviewed 
in53]. The PKC family consists of at least 10 isozymes with distinct and in some cases 
opposing roles in cellular processes, such as cell growth, differentiation, survival and 
apoptosis. This family is divided into three subfamilies according to their primary structure 
and cofactors required for activation: conventional or classic PKCs (cPKCs: PKCα, PKCβI, 
PCKβII and PKCγ), novel PKCs (nPKC: PKCδ, PKCε, PKCη and PKCθ) and atypical PKCs 
(aPCKS: PKCζ and PKCλ) (Figure 7) [reviewed in53b, 54]. 
The principal co-factors required for PKC activity are calcium, phosphatidylserine (PS) 
and diacylglycerol (DAG), a lipid second messenger transiently generated upon stimulation 
of membrane receptors such as tyrosine-kinase and G-protein coupled receptors [reviewed 
in53b, 55]. The differences between the distinct subfamilies reside in the regulatory domain. 
The C1 domain that comprises two cysteine-rich motifs forming the DAG binding site has 
only one cysteine-rich in aPKCs, and is not able to bind DAG. The C2 domain, that binds 
calcium and PS in cPKCs, is altered in nPKCs and aPKCs, losing the ability to bind calcium. 
In turn, C3 domain acts as an ATP binding site and C4 domain as a kinase catalytic centre 
[reviewed in56]. 
 
 
Figure 7 – PKC family structure. The three subfamilies are represented, as well as, their distinct bindings. The 
table on the right summarizes the second messengers that bind to each subfamily of PKC, with (+) representing 
binding, (++) representing binding with∼100-fold higher affinity, (+++) representing binding with >100-fold higher 
affinity, and (−) representing lack of binding. Abbreviations: aC1 – atypical C1 domain; DAG – diacylglycerol; 
nC2 – novel C2 domain; PB1 - Phox and Bem 1 domain; PS – phosphatidylserine. Adapted from57.  
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Individual PKC isoforms can exert either similar or opposite effects in cell proliferation 
and death, so an individual analysis of PKC isoforms would contribute to the identification 
of isoform-selective pharmacological modulator [reviewed in58]. The PKC isoform-specificity 
is basically a result of isoform-specific patterns of subcellular compartmentalization, protein-
protein interactions and post-translational modifications. The specificity of each PKC 
isoform is therefore highly dependent on its primary structure, which determines the 
requirement for activating co-factors, regulatory phosphorylations, and intra- and inter-
molecular interactions59. 
The existence of PKC isoforms with differential activation and tissue distribution raised 
the possibility to the development of PKC isoform-specific modulators with the potential to 
target specific intracellular pathways. However, the current PKC modulators that have 
reached the clinic are relatively non-specific [reviewed in54a, 58, 60]. This may be due to the 
highly similarity of the catalytic domain of PKC compared to many other protein kinases. 
Rottlerin is an example of a non-selective PKC modulator that is highly used to study the 
role of PKCδ. Nevertheless, rottlerin is a potent large conductance potassium channel 
opener that affects multiple other protein kinases [reviewed in61]. 
Loss-of-function mutations were observed in all PKC subgroups, and were associated 
with the prevention of second-messenger binding, phosphorylation, or catalysis62. PKC 
levels are aberrant in a variety of cancers and over 400 mutations in PKC have been 
identified in human cancers63. Recently, from 37 mutations studied, 24 reduced or 
completely abolished the PKC activity63. 
Altogether, based on the exposed above, isoform-selective pharmacological modulators 
are highly necessary, in order to target specific intracellular pathways to help in the 
prevention of cancer development. Despite the importance of all PKC-isoforms in cancer, 
this dissertation will be focused on the study of nPKC-δ. 
  
Protein kinase C δ 
PKCδ was the first identified member of the nPKC subfamily. PKCδ has been implicated 
in the regulation of both intrinsic and extrinsic apoptosis pathways. Indeed, the 
overexpression or activation of PKCδ results in the induction of apoptosis [reviewed in64]. 
During apoptosis, PKCδ is proteolytically cleaved by caspase-3 and translocates from the 
cytoplasm to the nucleus after treatment with genotoxic agents to generate a constitutively 
activated catalytic fragment, which amplifies apoptotic cascades. Other studies showed that 
PKCδ-mediated apoptosis involves the allosteric activation of the enzyme rather than 
proteolytic cleavage. Nevertheless, the complex role of PKCδ in apoptosis appears to be 
stimulus and cell type dependent [reviewed in55b, 64].  
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In fact, PKCδ can be activated by distinct apoptotic stimuli such as DNA damaging 
agents, ultraviolet (UV) radiation, and reactive oxygen species (ROS) [reviewed in64]. 
PKCδ is frequently associated with pro-apoptotic functions. Thus, this isoform has been 
largely implicated as a cell death mediator of chemotherapeutic agents and radiotherapy, 
since can be involved in both DNA damage and receptor-mediated cell death [reviewed 
in55b]. In fact, in 1993, it was reported that overexpression of PKCδ induced growth inhibition 
in NIH 3T3 cells65, an effect also observed in other cell lines. For instance, it was 
demonstrated that the anti-proliferative effects of retinoic acid were dependent on PKCδ in 
leukemic and MCF-7 cells, indicating that the endogenously expressed PKCδ can suppress 
cell proliferation66. On the other hand, pro-survival properties of PKCδ in a number of tumour 
models, including breast, lung, pancreatic and liver cancer, were also described [reviewed 
in67].  
Despite this, most studies around the effects of this isoform on cell proliferation indicate 
an inhibitory effect of this protein on cell proliferation. Nevertheless, it has been proposed 
that PKCδ has both tumour suppressor and proliferation capabilities that can be recruited 
as a backup kinase for both gatekeeper tumour suppression and as an activator of the 
Ras/Raf/MEK/MAP kinase signaling pathway in cell proliferation [reviewed in68]. Loss of 
PKCδ expression has been reported in some cancer types, such as, endometrial tumours69, 
malignant fibrous histiocytoma70 and human squamous cell carcinomas71. 
Hence, due to the relevant role of the PKCδ in the apoptotic process, the search for 
selective activators of this PKC isoform is an attractive and appealing therapeutic strategy 
in cancer therapy.  
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1.2.2.1. MODULATORS OF PKC FAMILY PROTEINS  
 
A wide range of small molecule PKC activators and inhibitors (Table 1) have emerged 
to modulate the activity, subcellular distribution, protein interactions and life cycle of PKC 
[72; reviewed in57]. 
 
Table 1 – Mechanism of action and selectivity of PKC small molecule modulators. 
 
 
 
Compounds 
 
 
Mechanism of action 
 
 
Selectivity to PKC 
 
 
References 
 
Small molecule activators  
 
 
PMA 
(Phorbol-12-myristate-
13-acetate) 
 
Activate PKC via any of 
the cysteine motifs in the 
C1 domain 
 
Not well characterized on 
PKCε 
No effect on PKCζ 
 
 
72-73 
 
dPPA 
(12-deoxyphorbol 13-
phenylacetate 20-
acetate) 
 
Activate PKC via any of 
the cysteine motifs in the 
C1 domain 
 
 
No effect on PKCα, PKCδ, 
PKCε and PKCζ 
 
 
72-73 
 
 
 
Mezerein 
 
Preferably active for the 
first cysteine repeat of the 
C1 region 
 
Not well characterized on 
PKCε and PKCη 
No effect on PKCζ 
 
 
72, 74  
 
 
 
Bryostatin 1 
 
 
Preferentially binds to the 
second cysteine repeat. 
Induces direct 
translocation to internal 
membranes 
 
 
 
Selectively activates PKC-δ 
and PKC-ε. 
 
 
 
 
72, 75 
 
 
Coleon U 
 
 
Induction of a Yca1p- and 
mitochondrial-dependent 
apoptosis 
 
Selectively activates PKCδ 
and PKCε 
No effect on PKCα, PKCβI 
and PKCζ 
 
 
74, 76 
 
Small molecule inhibitors  
 
 
Chelerythrine 
 
 
Induces apoptosis 
 
 
 
None 
 
 
57, 76 
 
 
Calphostin C 
 
Competes against 
DAG/phorbol ester 
binding C1 domain. 
 
 
Not well characterized 
 
 
57 
 
PS168, PS171 
Benzimidazole 
compounds 
 
 
Inhibits allosterically 
 
 
Selectively inhibits PKCζ  
 
57 
 
 
Rottlerin 
 
 
Mitochondrial uncoupler 
 
None 
No effect on PKCα 
 
 
57, 76 
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In 1982, it was discovered a natural phorbol ester, the phorbol 12-myristate 13-acetate 
(PMA) (Figure 8), as a PKC activator. This compound mimicked DAG without generation 
of this unsaturated lipid. Moreover, it was established that phorbol esters competitively act 
with DAG for the same binding site and activate PKC in a similar manner77. These findings 
opened the way to the research of the PKC involvement in cell growth and tumour 
promotion. Additionally, they established the use of phorbol esters as crucial tools for the 
manipulation of PKC activity in cells, allowing the elucidation of a wide range of cellular 
processes regulated by these enzymes. 
 
 
 
 
 
Figure 8 – Chemical structure of PMA. 
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1.3. FLAVONOIDS AS PROMISING ANTICANCER AGENTS 
 
Flavonoids are naturally occurring compounds that belong to a large group of plant 
secondary metabolites, which can be found in all plant parts, including in many fruits and 
vegetables [reviewed in77b]. These compounds have a C6-C3-C6 carbon framework, that is, 
two aromatic rings (A and B) linked by a three carbon unity that may form a third ring (C). 
This basic structure occurs in a variety of structural forms, being subdivided into different 
classes, including flavanones, flavones, flavonols, isoflavones, dihidroflavonols, chalcones, 
dihidrochalcones, flavans, flavan-3-ol, isoflavones, and anthocyanidins, among others 
(Figure 9) [reviewed in78]. 
 
 
 
 
Figure 9 - Basic skeleton and numbering pattern of some flavonoid classes. 
 
 
It is well-known that flavonoids and their synthetic analogues have therapeutic 
potential as anticancer agents, inhibiting various stages in the carcinogenesis process 
(Figure 10) [reviewed in78].  
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Figure 10 - Flavonoids antitumor activities. 
 
 
In fact, these natural compounds are able to inhibit the tumour cell growth, an event 
associated with apoptosis induction (Table 2)79. However, in most of the tumour cells the 
molecular mechanism by which such compounds can induce apoptosis have not yet been 
clarified. Despite that, several mechanisms have been proposed, for example, decrease of 
ROS, release of cyt c with a subsequent activation of caspases-9 and -3, downregulation 
of Bcl-2 and Bcl-X(L) expression, and stimulation of Bax and Bak pro-apoptotic protein 
expression, among others [reviewed in80]. Another possible mechanism for the potential 
antitumor effects of flavonoids is their ability to inhibit various PKCs, thereby inhibiting signal 
transduction events of cell proliferation. In fact, some flavones and flavonols have shown to 
inhibit efficiently PKCs [reviewed in77b]. 
The potency of flavonoids for inducing apoptosis may be dependent on the number 
of hydroxyl groups in the 2-phenyl ring and on the absence of the 3-hydroxyl group 
[reviewed in81]. Actually, it is noted that the hydroxylation pattern of the B ring of the flavones 
and flavonols, such as luteolin and quercetin, seems to be critical for their activities, 
especially to the inhibition of the activity of protein kinases [reviewed in78a]. 
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Table 2 – Flavonoids with antitumor activity in distinct human tumour cells. 
 
 
Flavonoid 
 
Antitumor activity 
 
Human tumour cells 
 
References 
 
  
 
 
Luteolin 
 
 
 
 
Inhibits proliferation; 
Induces G2/M-phase 
cell cycle arrest; 
Induces Apoptosis. 
 
Human esophageal 
squamous adenocarcinoma 
KYSE-510 cells; lung 
carcinoma CH27 cells and 
human colon cancer HT-29 
cells.  
 
 
 
82 
 
 
Genistein 
 
Induces G2/M-phase 
cell cycle arrest; 
Induces apoptosis. 
 
 
---- 
 
 
83 
 
 
 
Quercetin 
 
Induces G2/M-phase 
cell cycle arrest; 
Induces apoptosis 
trough a p53-
dependent mechanism 
and trough the release 
of cyt c. 
 
 
 
Human leukaemia HL-60 
cells. 
 
 
 
 
84 
 
 
 
Baicalein 
 
 
 
Induces apoptosis 
 
Human colorectal 
adenocarcinoma HT-29 cells 
and human epithelial 
colorectal adenocarcinoma 
Caco-2 cells. 
 
 
 
84b, 85 
 
 
 
 
 
Apigenin 
 
 
 
Induces apoptosis 
 
Human colorectal 
adenocarcinoma HT-29 
cells; human epithelial 
colorectal adenocarcinoma 
Caco-2 cells and human 
leukaemia HL-60 cells. 
 
 
 
84b, 86 
 
In conclusion, flavonoids interact with a wide range of molecular targets involved in 
apoptosis and cell proliferation pathways by affecting their expression or activity. 
Accordingly, it is reasonable to consider this scaffold as a valuable basis for the 
development of new and more potent pro-apoptotic agents that could be relevant for  cancer 
treatment [reviewed in87]. 
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1.4. YEAST AS A MODEL SYSTEM 
 
1.4.1. YEAST AS A MODEL TO STUDY HUMAN PROTEINS  
 
In the last few years, the budding yeast Saccharomyces cerevisiae has provided a major 
contribution on the understanding of the pathobiology of some human diseases. In fact, the 
high degree of conservation of cellular and molecular processes between the yeast S. 
cerevisiae and higher eukaryotes have made this microorganism a valuable model system 
for numerous studies on devastating human disorders such as cancer [reviewed in60, 76, 88]. 
Easy manipulation, short generation time, a well-defined genetic system and a high 
amenability to genetic modifications represent advantages of yeast cells over other cell 
models. However, as a unicellular organism, the limitation of this cell system for the study 
of human diseases concerns in the analysis of disease aspects that rely on multicellularity 
and cell-cell interactions. In fact, some disease-associated genes may not be present in 
yeast [reviewed in60, 89]. In spite of this limitation, yeast has provided a valuable contribution 
in the discovery of mechanistic processes involved in the cancer disease. For instance, with 
the finding that yeast can undergo an apoptotic cell death exhibiting phenotypic features 
and basic molecular machinery similar to those found in higher eukaryotes, the mechanisms 
of apoptosis could also be intensively addressed in yeast and the knowledge obtained 
transposed to human cells, providing clues towards an understanding of apoptosis-related 
diseases, such as cancer [reviewed in90]. In fact, the yeast model system has been 
considered a useful tool to study cancer-related proteins. If a gene encoding a protein is 
conserved in yeast, it is possible to directly study its function in this organism. On the other 
hand, if the gene has no orthologues in yeast, its heterologous expression in this cell model 
can still be highly informative because yeast may conserve protein interactions that may 
give crucial clues to the gene function. In fact, the absence of orthologues of a protein or an 
entire pathway can sometimes be an advantage because the protein can be independently 
studied in a simpler eukaryotic system, without the interference of other proteins that can 
share similar or overlapping functions  [reviewed in60].  
Based on the exposed above, in the last few years, the yeast cell model has been used 
not only to study the biology of important molecular processes, but also to study the 
pharmacology of proteins involved in cancer.  
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1.4.2. YEAST AS A MODEL FOR TARGETED SCREENING ASSAYS 
 
The simplicity of yeast genetics has made this cell model a promising system for 
identifying and testing target-specific drug therapies. Indeed, due to several advantages 
over cell-free and human cell-based assays (Table 3), yeast has emerged as a valuable 
tool for genetic and chemical large-scale screenings [reviewed in89a, 91].  
 
Table 3 – Advantages and drawbacks of yeast targeted screening assays over other widely used 
assays. Adapted from76. 
 
 
Yeast target directed screening assays 
 
Advantages 
 
Drawbacks 
 
Remarks 
 
Over cell-free assays 
 
Over human cell based 
assays 
Are not the most 
physiologically 
relevant model 
system; 
Tests in mammalian 
are crucial to validate 
the pharmacological 
relevance of the 
targets identified. 
Cell wall does not 
limit compound 
permeability; 
Yeast pleiotropic 
drug resistance 
exporter proteins 
are structurally 
similar to the 
mammalian multiple 
drug resistance 
efflux pumps. 
Purification of the 
target is not required; 
Target proteins are 
examined in a cellular 
environment; 
Selection against 
compounds that are 
generally cytotoxic, 
instable in a cell culture 
or that cannot 
permeate plasma 
membrane. 
 
 A clean read-out in a 
null background 
environment for the 
expression of the human 
protein; 
Less expensive to 
culture; 
Faster growth in defined 
media; 
Easier to propagate in 
HTS automated 
systems; 
Multitude of genetic tools 
and cellular selection 
systems readily 
converted to HTS 
formats. 
 
 
In the last years, humanized yeast cells have emerged as a useful model in the first-line 
drug screening, particularly in targeted screenings where the activity of a defined human 
protein is measured. Indeed, yeast can contribute to drug discovery through the 
identification of compounds that cause a desired physiological change through modulation 
of a specific protein [reviewed in76].  
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Most of the human proteins involved in cancer (e.g. caspases) are toxic when 
overexpressed in yeast, since are able to interfere with the growth-regulatory pathways of 
this microorganism. Based on this, the restoration of the yeast cell growth is the basis of 
several chemical and genetic screenings for inhibitors of human target proteins. In the same 
way, the increase of the growth arrest induced by the foreign protein is the basis of several 
screenings for activators of human target proteins92. Indeed, when used a yeast model in 
the first step of the drug discovery process, coupled with other complementary approaches 
in mammalian systems, it can have an important impact in the discovery of new therapeutic 
opportunities [reviewed in93]. 
The yeast targeted screening assays are developed based on the use of the gene 
overexpression technique. In the last years, genome-wide yeast overexpression libraries 
have been created, taking advantage of the high amenability of this microorganism to 
genetic alterations. In fact, due to this organism be easily transformed by extrachromosomal 
plasmids, the selection of transformed cells is quite straightforward, and there are several 
regulatable promoters available that allow a considerable control over gene expression 
[reviewed in76]. The gene overexpression technique consists on the use of a high-copy 
library, in which a cDNA from a library of human cDNAs, is expressed under a regulatable 
promoter, inserted in yeast expression vectors (Figure 11) [reviewed in76]. These 
overexpression libraries have been applied to studies concerning human disease-
associated proteins that induce a screenable phenotype, like growth arrest, such as 
caspases [reviewed in76].  
 
 
 
 
Figure 11 – Gene overexpression technique. The insert of a gene encoding a protein of interest in yeast results 
in an engineered yeast cell, which can be used to study the biology and the pharmacology of proteins that play 
a central role in human disorders. 
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1.4.3. HUMAN PROTEINS STUDIED IN YEAST 
 
Based on the exposed above, during the last years, our research group has been 
focused on the development of yeast targeted screening assays to search for modulators 
of the activity of  distinct cancer-related human proteins, such as caspases, PKC family 
proteins, among others [reviewed in56, 60, 76, 94].  
 
 
1.4.3.1. CASPASE FAMILY PROTEINS 
 
Based on the high complexity of caspases-signalling pathways, the yeast cell mode has 
been used as a simpler cell system for an independent analysis of human caspase family 
members in order to identify specific regulators and substrates [reviewed in76]. Indeed, 
several yeast assays have recently been developed for the HTS of modulators of human 
caspases, using either chemical or cDNA libraries. The exploitation of these assays to 
screen for activators and inhibitors of individual caspase family members may help in the 
discovery of new therapeutic agents against cancer [reviewed in60]. 
Yeast encodes a metacaspase (Yca1p)95. Metacaspases are found only in eukaryotes 
that are devoid of caspases, such as yeast. In fact, Yca1p shares structural homology and 
mechanical characteristics with mammalian caspases. However, metacaspases have a 
different cleavage specificity than mammalian caspases96. Although the controversy, recent 
studies have demonstrated that the activity of human caspases in yeast is independent of 
Yca1p97. 
The caspase activity in yeast has been frequently associated with the induction of a cell 
death phenotype. However, it was found that the phenotypic consequences of the 
expressed human caspase in yeast were highly dependent on the yeast strain used, 
probably a result of differences in the expression levels of endogenous caspase substrates 
or of other proteases with similar functions among the yeast strains [reviewed in76]. 
 In fact, several aspects of the regulation of mammalian caspases could be 
recapitulated in yeast. For instance, it was reported in 2000 that IAPs in mammals, namely 
XIAP, suppressed the growth defect of S. cerevisiae expressing active human caspase-398. 
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Meanwhile, while the majority of mammalian caspases are auto-activated in yeast 
when expressed at high levels, downstream caspases, as caspases-3, -6 and -7, and the 
initiator caspase-9 cannot undergo auto-activation. In fact, these caspases require for their 
activation mammalian upstream proteins, such as initiator caspases or the Apaf-1, which 
are absent in yeast [reviewed in18, 23]. Indeed, this has been bypassed using engineered 
autoactivated variants that allow auto-activation of these caspases even in the absence of 
their upstream activators (Figure 12). 
 
 
 
Figure 12 - Different strategies of human caspases-3, -6 or -7 activation in S. cerevisiae. (A) Natural caspase 
activators; (B) Generation of reverse caspase, in which the small subunit precedes its prodomain and large 
subunit; (C) Removal of the N-terminal prodomain from the caspase coding sequence; (D) Separately co-
expressing the large and small subunits of an active caspase; (E) Joining in-frame the caspase cDNA to the 
coding regions for Escherichia coli β-galactosidase (lacZ). Activated caspases lead to yeast growth arrest. 
Catalytic cysteine represented in purple. Abbreviations: LS, large subunit; SS, small subunit. Adapted from60. 
 
 
The most commonly used strategy for studying human caspases in yeast has relied on 
the fact that high expression levels of a caspase lead to a pronounced yeast cell growth 
arrest. Based on this, yeast can be used as a system to search for pharmacological 
modulators of this family of proteins (Figure 13) [reviewed in60]. 
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Figure 13 - The use of a yeast-based screening assay to search for modulators of procaspases-3 and -7, 
followed by an in vitro processing assay and assays in human tumour cell lines, led to the identification of 
activators of these proteins99. 
 
 
1.4.3.1.1. POTENTIAL PHARMACOLOGICAL MODULATORS OF CASPASES 
IDENTIFIED IN YEAST 
 
In 2011, Glória and colleagues developed a yeast targeted screening assay to search 
for caspase-3 pharmacological activators. This assay is based on the measurement of yeast 
cell growth, particularly on the correlation established between the reversion of caspase-3-
induced yeast growth inhibition by a caspase-3 inhibitor and the inhibition of caspase-3 
activity. The use of this assay to screen for modulators of individual caspase family 
members may help in the discovery of new therapeutic agents, namely, against cancer. In 
fact, this assay led us to the discovery of new inhibitors of caspase-3 among a chemical 
library of vinyl sulfones100.  
More recently, the use of a yeast approach developed to search for caspase-7 
modulators also led us to the identification of potential small molecule activators of caspase-
7 with a flavonoid scaffold, being this activity also supported by in vitro processing assays 
and by assays in human tumour cell lines99. In this study, flavonoids 1a (5,6-dihydroxy-7-
prenyloxyflavone) and 2a (3-hydroxy-7-geranyloxyflavone) (Figure 14) were identified as 
activators of caspase-7, without interfering with the activity of caspase-3. Indeed, the yeast 
model provided important data concerning structural requirements for the activity of 
flavonoids towards caspase-799. 
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Figure 14 – Chemical structure of the flavonoids activators of caspase-7 identified using a yeast 
screening assay: compound 1a and compound 2a. 
 
1.4.3.2. PKC FAMILY PROTEINS 
 
In 2003 Riedel and collaborators showed, for the first time, that yeast was an efficient 
model system for the evaluation of the activity of specific mammalian PKC isoforms, due to 
the yeast Pkc1p be a structural but not a functional homologue of mammalian PKC 
isoforms101. Indeed, yeast arose as a promising cell system for an individual analysis of 
mammalian PKC isoforms expressed in a simpler eukaryotic cellular environment without 
the interference of other isoforms or endogenous regulators [reviewed in76]. 
The catalytic function of mammalian PKC isoforms expressed in yeast was confirmed 
by monitoring the phosphorylation of specific PKC substrates. Particularly, the ability of 
mammalian PKC isoforms (namely PKCα, δ and ζ) to modulate the phosphorylation state 
of human proteins, such as Bcl-xL102 and p53103 in yeast was also demonstrated. 
The activation of a mammalian PKC isoform in yeast induced a specific phenotype and 
an increase in the cell doubling time proportional to the level of its enzymatic activity. These 
features led to the establishment of a yeast PKC phenotypic assay [reviewed in56]. The use 
of this yeast assay as a tool for the screening of several chemical libraries has led to the 
identification of new potential PKC pharmacological modulators [reviewed in56].   
In fact, in this assay the PMA-induced growth inhibition in yeast cells expressing a 
mammalian PKC isoform is proportional to the degree of PKC activation, whilst known PKC 
inhibitors, such as chelerythrine or NPC 15437, reverted the effects of PKC activators. 
Indeed, the use of the yeast-based PKC assay in the screening of several chemical libraries 
led to the identification of new potent PKC activators and inhibitors, some of them selective 
to a particular isoform, such as PCKδ, PKCη and PKCζ [reviewed in56, 76]. 
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1.4.3.2.1. POTENTIAL PHARMACOLOGICAL MODULATORS OF PKC IDENTIFIED 
IN YEAST 
In 2004, with yeast cells expressing PKCα, PKCβI, PKCδ, PKCη or PKCζ, the potency 
and selectivity of the known PKC activator, PMA and its analogues MPMA (phorbol-12-
myristate-13-acetate-4-O-methyl-ether) and 4αPMA have been characterised104. 
Interestingly, MPMA and 4αPMA were identified as PKC inhibitors in contrast to their 
starting material104. In a previous work from the same group, the activity of daphnetoxin and 
its derivative mezerein has been compared, in yeast expressing PKCα, PKCβI, PKCδ or 
PKCζ, in order to investigate differences in their selectivity as PKC activators. In fact, 
daphnetoxin showed much lower potency to activate the PKCδ isoform and higher potency 
to activate PKCα, comparatively to mezerein72. Once again, using yeast, the molecular 
mechanism of action of the PKC activator euxanthone was ascertained, showing 
remarkable selectivity for PKCζ105. 
More recently, the activity of coleon U (6,11,12,14-tetrahydroxy-abieta-5,8,11,13-
tetraene-7-one) (Figure 15), a diterpene compound with an antiproliferative effect on 
human tumour cells (e.g. MCF-7 and UACC62), was demonstrated on individual isoforms 
of the distinct PKC subfamilies, using a yeast PKC assay (Figure 16). 
 
 
 
 
 
Figure 15 – Chemical structure of coleon U. 
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This study showed that coleon U induces the translocation of PKCδ and ε, in yeast 
expressing these proteins, to the nucleus, an effect associated with the induction of a 
Yca1p- and mitochondrial-dependent apoptosis. Additionally, it was also demonstrated that 
the PKC activator PMA was able to activate all PKCs tested except aPCKζ, while coleon U 
had no effect on aPKC and cPKCs. Besides, the effect of coleon U on nPKCs was higher 
than that of PMA. Therefore, using the yeast screening assay it was possible to determine 
that coleon U was a potent and selective activator of nPKCs, inducing an apoptotic yeast 
cell death only in yeast cells expressing  PKCδ or ε isoforms (Figure 16)74. 
 
 
 
 
 
Figure 16 - Molecular mechanism of action of coleon U in yeast cells. Coleon U had no effect on yeast cells 
expressing aPKC and cPKCs. On the other hand, in yeast expressing PKCδ or ε, coleon U induced the 
translocation of these proteins to the nucleus and a Yca1p- and mitochondrial-dependent apoptosis, which was 
abolished by the co-expression in yeast of the human anti-apoptotic protein Bcl-xL. 
 
Taken together, these results showed that the yeast PKC model can efficiently 
contribute not only to the discovery of new PKC isoform-selective modulator with promising 
therapeutic applications, but also to unravel the molecular mechanism of action underlying 
their pharmacological activities, as observed with coleon U [reviewed in56]. Additionally, 
important insights concerning the mechanisms of apoptotic function of PKC isoforms, and 
physiologically relevant substrates have been provided by the yeast PKC assays (Table 4) 
[reviewed in60]. 
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Table 4 – Effects of mammalian PKC isoforms on distinct apoptotic stimuli and human apoptotic 
proteins expressed in yeast. Adapted from60. 
 
 cPKCα nPKCδ nPKCε aPCKζ 
Apoptotic stimuli 
Acetic acid ↑ ↑ ↑ ↑ 
H2O2 NE NE ↑ NE 
Coleon U NE ↑ ↑ NE 
Apoptotic proteins 
Bcl-xL ↓ NE ↑ ↑ 
Bax ↑ - - - 
p53 NE ↑ ↑ NE 
 
Legend: Up arrow (↑), increase of effect; Down arrow (↓), decrease of effect; NE, No effect; not determined. 
 
 
In conclusion, the yeast PKC assays have provided valuable insights into the 
molecular and functional profile of individual PKC isoforms. Furthermore, potent and 
selective small molecule modulators of these kinases have been also identified. Indeed, the 
yeast screening assay represents an important contribution to the design of new therapeutic 
strategies against cancer through the identification of key apoptotic targets amongst the 
PKC family isoforms [reviewed in60]. 
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1.5. SCOPE OF THIS DISSERTATION 
 
The present dissertation in Pharmaceutical Chemistry aimed the search for new 
potential small molecule modulators of the pro-apoptotic proteins of the caspase and PKC 
family, using the yeast-based screening assay. Particularly, with this work, it was intended 
to identify new activators of caspases-3, -6 and -7 with a flavonoid scaffold and with 
improved pharmacological activities compared to those described by our group in previous 
work. Additionally, it was intended to analyse the in vitro antitumor potential of compound 
C4, previously identified in a yeast cell-based assay as a potential PKCδ isoform-selective 
pharmacological activator. Collectively, with this project, it was intended to provide new 
pharmacological alternatives to be explored as potential therapeutic strategies against 
cancer. 
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CHAPTER 2 
 
 
 
 
 
 
Material and Methods 
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2.1. CASPASE FAMILY PROTEINS 
2.1.1. CHEMISTRY 
 
Chemicals were purchased from Sigma-Aldrich (Sintra, Portugal). Three flavonoid 
derivatives were investigated: 7-(allyloxy)-5,6-dihydroxy-2-phenyl-4H-chromen-4-one (S1), 
5,6-dihydroxy-2-phenyl-7-propoxy-4H-chromen-4-one (S2) and 5,6-dihydroxy-7-
(isopentyloxy)-2-phenyl-4H-chromen-4-one (S3). These compounds were obtained under 
the master’s dissertation of BSc Joana Patrícia Martins Moreira. Briefly they were 
synthesized by the MW irradiation of Baicalein with 1.6 eq. of alkylating agent (isopentyl, 
propyl or allyl iodide) in the presence of anhydrous potassium carbonate. MW reactions 
were performed using a glassware setup for atmospheric-pressure reactions and a 100 mL 
Teflon reactor (internal reaction temperature measurements with a fiber-optic probe 
sensor), and were carried out using an Ethos MicroSYNTH 1600 Microwave Labstation from 
Milestone (Australia). All the reactions were monitored by thin-layer chromatography (TLC). 
Melting points were obtained in a Köfler microscope and are uncorrected. IR spectra were 
measured on an ATI Mattson Genesis series FTIR (software: WinFirst, v. 2.10) 
spectrophotometer in KBr microplates (cm-1). Purification of compounds was carried out by 
flash chromatography using Macherey-Nagel silica gel 60 (0.04-0.063 mm), preparative 
TLC using Macherey-Nagel silica gel 60 (GF254) plates, and crystallization. 1H and 13C 
NMR spectra were taken in CDCl3 at r.t., on Bruker Avance 300 instruments (300.13 MHz 
for 1H and 75.47 MHz for 13C). Chemical shifts are expressed in δ (ppm) values relative to 
tetramethylsilane (TMS) used as an internal reference; 13C NMR assignments were made 
by 2D (HSQC and HMBC) NMR experiments (long-range 13C-1H coupling constants were 
optimized to 7 Hz).  
PAC-1 and M1541 were obtained from Calbiochem (VWR, Carnaxide, Portugal). All 
tested compounds were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, Sintra 
Portugal). 
 
2.1.1.1. GENERAL PROCEDURES FOR THE PREPARATION OF BAICALEIN 
DERIVATES 
A mixture of baicalein (0.20 g, 0.74 mmol), isopentyl/ propyl/ allyl iodide (1.18 mmol) 
and anhydrous K2CO3 (0.55 g, 3.7 mmol) in anhydrous acetone (60 mL) was submitted to 
successive 30 min of microwave irradiation at 200 W of potency. The final temperature was 
60 °C and the total irradiation time was 2 h, except for the reaction with isopentyl iodide, for 
which the reaction time was 3 h. After cooling, the solid was filtered and the solvent removed 
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under reduced pressure to afford the crude product. The yellow-orange solid obtained was 
dissolved in acetone and purified as described below. 
 
2.1.1.1.1. 7-(allyloxy)-5,6-dihydroxy-2-phenyl-4H-chromen-4-one (S1). Purified by 
flash chromatography (SiO2; n-hexane: EtOAc). Yield: 4.2% as yellow crystals; mp 160-162 
ºC; IR (kBr) ʋmax: 3447, 2925, 2923,2854, 1663, 1576, 1489, 1449, 1252 cm-1; 1H NMR 
(CDCl3, 300.13 MHz) δ= 13.04 (OH, s, H-5), 7.90-7.87 (2H, m, H-2’,6’), 7.58-7.49 (3H, m, 
H-3’,4’,5’), 6.68 (1H, s, H-3), 6.63 (1H, s, H-8), 6.18-6.05 (1H, m, H-2’’), 5.51-5.45 (1H, m, 
H-3’’a), 5.41-5.37 (1H, m, H-3’’b), 4.74 (2H, d, J=5.4, H-1’’); 13C NMR (CDCl3, 75.47 MHz) 
δ= 182.6 (C4), 164.1 (C2), 151.7 (C7), 150.5 (C8a), 145.8 (C5), 131.8 (C2’’), 131.4 (C1’), 
129.1 (C3’,5’), 126.2 (C2’,6’), 131.8 (C4’), 129.8 (C6), 119.1 (C3’’), 106.1 (C4a), 105.4 (C3), 
91.6 (C8), 70.2 (C1’’). 
 
2.1.1.1.2. 5,6-dihydroxy-2-phenyl-7-propoxy-4H-chromen-4-one (S2). Purified by 
flash chromatography (SiO2; petroleum ether: EtOAc). Yield: 6 % as yellow crystals; mp 
167-170 ºC; IR (kBr) ʋmax: 3441, 2927, 2922, 2851, 1617, 1559, 1489, 1473, 1459, 1458 
cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 12.50 (OH, s, H-5), 7.91-7.88 (2H, m, H-2’,6’), 7.55-
7.52 (3H, m, H-3’,4’,5’), 6.69 (1H, s, H-3), 6.61 (1H, s, H-8), 5.37 (OH, s, H-6), 4.12 (2H, t, 
J=5.9, H-1’’), 2.05-1.98 (2H, m, H-2’’), 1.10 (3H, t, J=7.4, H-3’’); 13C NMR (CDCl3, 75.47 
MHz) δ= 182.7 (C4), 164.0 (C2), 152.3 (C7), 150.7 (C8a), 145.6 (C5), 131.7 (C4’),131.6 
(C1’), 129.7 (C6), 129.1 (C3’,5’), 126.2 (C2’,6’), 106.0 (C4a), 105.4 (C3), 91.1 (C8), 71.0 
(C1’’), 22.3 (C2’’), 10.4 (C3’’). 
 
2.1.1.1.3. 5,6-dihydroxy-7-(isopentyloxy)-2-phenyl-4H-chromen-4-one (S3). 
Purified by flash chromatography (SiO2; n-hexane: EtOAc). Yield: 5.6 % as yellow crystals; 
mp 175-178 ºC; IR (kBr) ʋmax: 3440, 2955, 2921, 2854, 1657, 1489, 1477, 1450, 1115 cm-
1; 1H NMR (CDCl3, 300.13 MHz) δ= 7.91-7.88 (2H, m, H-2’,6’), 7.54-7.52 (3H, m, H-3’,4’,5’), 
6.69 (1H, s, H-3), 6.62 (1H, s, H-8), 4.18 (2H, t, J=6.6, H-1’’), 1.93-1.77 (2H, m, H-2’’), 1.25 
(1H, m, H-3’’), 1.01 (6H, d, J=6.3, H-4’’,5’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.7 (C4), 
164.0 (C2), 152.3 (C7), 150.7 (C8a), 145.6 (C5), 131.5 (C1’), 126.2 (C2’,6’), 129.7 (C6), 
129.1 (C3’,5’), 131.8 (C4’), 106.0 (C4a), 105.4 (C3), 91.0 (C8), 68.0 (C1’’), 37.5 (C2’’), 29.7 
(C3’’), 22.7 (C4’’), 22.6 (C5’’). 
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2.1.2. BIOLOGICAL ACTIVITY 
 
2.1.2.1. YEAST TARGETED SCREENING ASSAY 
 
Sacharomyces cerevisiae (strain CG379 Matα, ade5, his2, leu2-112, trp1-289, ura3-52 
[Kil-O]) (Yeast Genetic Stock Center, University of California, USA) expressing each human 
procaspase-3, -6 or -7 was obtained in a previous work99. For expression of human proteins 
(routinely grown in minimal selective medium), yeast cells were diluted to 0.05 optical 
density at 600 nm (OD600) in induction selective medium with 2% (w/w) galactose (Sigma-
Aldrich, Sintra, Portugal),  1% glycerol (Sigma-Aldrich, Sintra, Portugal), 0.7% (w/w) yeast 
nitrogen base without amino acids from Difco (Quilaban, Sintra, Portugal), and all the amino 
acids required for yeast growth (50 µg/ml) except leucine, and incubated at 30 ºC, under 
continuous orbital shaking (200 rpm). Yeast cells were incubated at 30 ºC under continuous 
orbital shaking (200 rpm) with 0.1-15 µM compounds S1-3, 0.1-50 µM  PAC-1, 0.1-5 µM 
M1541 or  0.1% DMSO only, for approximately 24 h (time required by the yeast transformed 
with the empty vector, control yeast, to achieve 0.3 OD600). Yeast growth was analyzed by 
counting the number of colony-forming units (CFU) after 2 days incubation at 30ºC on 
Sabouraud Dextrose Agar from Liofilchem (Frilabo, Porto, Portugal). For each culture, the 
percentage of drug-induced growth inhibition was estimated considering 100% growth the 
number of CFU obtained with yeast incubated with DMSO only.  
 
2.1.2.2. STASTICAL ANALYSIS 
Data were analysed statistically using the SigmaPlot 12.00. Differences between means 
were tested for significance using the Student’s t-test. Data are mean ± SEM of six 
independent experiment; *p=0.01, **p=0.001. 
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2.2. PROTEIN KINASE C FAMILY PROTEINS 
 
2.2.1. COMPOUNDS 
Phorbol 12-myristate 13-acetate (PMA) was obtained from Enzo Life Sciences (Group 
Taper, Sintra, Portugal) and 7α-acetoxy-6β-hydroxyroyleanone (C4) was synthesized as 
described in106. All tested compounds were dissolved in DMSO (Sigma-Aldrich, Sintra 
Portugal). 
  
2.2.2. HUMAN TUMOUR CELL LINES AND GROWTH CONDITIONS 
 
Human colon adenocarcinoma HCT116 cell line was kindly provided by Dr. A. Inga 
(CIBIO, University of Trento, Italy). HCT116 cell line was routinely cultured in RPMI-1640 
with ultraglutamine medium from Lonza (VWR, Carnaxide, Portugal) supplemented with 
10% fetal bovine serum from Gibco (Alfagene, Carcavelos, Portugal) and maintained in a 
humidified incubator at 37°C with 5% CO2. 
 
2.2.3. SULFORHODAMINE B (SRB) ASSAY  
 
For the analysis of the effect of C4 on the in vitro growth of human HCT116 cell line, 
cells were incubated in 96-well plates, at a final density of 5.0 × 103 cells/well, for 24 h. Cells 
were thereafter treated with serial dilutions of PMA (from 1.25 to 20.0 µM) and C4 (from 
0.23 to 3.6 μM). The effect of compounds on cellular integrity was analysed following 48 h 
incubation, using sulforhodamine B (SRB) assay. Briefly, following fixation with 10% 
trichloroacetic acid, plates were stained with 0.4% SRB both from Sigma-Aldrich (Sintra, 
Portugal), and washed with 1% acetic acid. The bound dye was then solubilized with 10 
mM Tris Base and the absorbance was measured at 510 nm in a microplate reader (Biotek 
Instruments Inc., Synergy MX, USA). The solvent of the compound (DMSO) corresponding 
to the maximum concentration used in this assay (0.1%) was included as control. The 
concentration of PMA and C4 that causes a 50% reduction in the net protein increase in 
cells during treatment (GI50, growth inhibition of 50%) was thereafter determined.  
 
2.2.4. ANALYSES OF CELL CYCLE AND APOPTOSIS  
 
HCT116 cells were plated in 6-well plates at a final density of 1.5 × 105 cells/well. After 
24 h incubation, cells were treated with the GI50 concentration of PMA, C4 or DMSO only 
for 24 h. For cell cycle analysis, cells were thereafter fixed in ice-cold 70% ethanol and 
incubated at 37ºC with RNase A from Sigma-Aldrich (Sintra, Portugal) at a final 
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concentration of 20 µg/mL for 15 min, and further incubated with 50 µg/mL propidium iodide 
(PI) from Fluka (Sigma-Aldrich, Sintra, Portugal) for 30 min, followed by flow cytometric 
analysis. For apoptosis analysis, cells were analysed by flow cytometry using the Annexin 
V-FITC Apoptosis Detection Kit I from BD Biosciences (Enzifarma, Porto, Portugal), 
according to the manufacturer’s instructions. 
 
2.2.5. WESTERN BLOT ANALYSIS 
 
Whole protein extracts from HCT116 human tumour cell lines were obtained as 
described 107. Protein extracts were quantified using the Coomassie staining Bradford from 
Sigma-Aldrich (Sintra, Portugal). Proteins (40 µg) were electrophoresed using a 10% SDS–
PAGE and transferred to a Whatman nitrocellulose membrane from Protan (VWR, 
Carnaxide, Portugal). Membranes were blocked with 5% milk and probed with a mouse 
monoclonal anti-PARP (C2-10) followed by an anti-mouse horseradish-peroxidase (HRP)-
conjugated secondary antibody. For loading control, membranes were stripped and 
reprobed with a mouse monoclonal anti-GAPDH (6C5). All antibodies were purchased from 
Santa Cruz Biotechnology (Frilabo, Porto, Portugal). The signal was detected with the ECL 
Amersham kit from GE Healthcare (VWR, Carnaxide, Portugal) and with the Kodak GBX 
developer and fixer from Sigma-Aldrich (Sintra, Portugal). 
 
2.2.6. FLOW CYTOMETRIC DATA ACQUISITION AND ANALYSIS 
 
For the flow cytometric analysis an Accuri™ C6 flow cytometer and the included 
acquisition software from BD Biosciences (Enzifarma, Porto, Portugal) were used. Cell 
cycle phases were identified and quantified using the FlowJo software (TreeStar Inc., 
Oregon, USA). 
 
2.2.7. STATISTICAL ANALYSIS 
 
Data were analysed statistically using the GraphPad Prism 6.0. Differences between 
means were tested for significance using the Student’s t-test. Data are mean ± SEM of tree 
independent experiment; *p<0.05, **p<0.01. 
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CHAPTER 3 
 
 
 
 
 
 
Results 
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3.1. CASPASE FAMILY PROTEINS 
 
IDENTIFICATION OF FLAVONOIDS S1, S2 AND S3 AS POTENTIAL ACTIVATORS OF 
CASPASE-7 USING A YEAST- BASED SCREENING ASSAY 
 
 In a previous work from our group, a yeast targeted screening assay was developed 
to search for small molecule modulators of human procaspases-3 and 7. Using this yeast 
approach, combined with in vitro assays and assays in human tumour cells, the prenylated 
flavonoids 1a (5,6-dihydroxy-7-prenyloxyflavone) and 2a (3-hydroxy-7-geranyloxyflavone) 
(Figure 14) were identified as potential activators of caspase-799. 
 In the present dissertation, this yeast screening approach was used to analyse the 
effect on the activity of human  procaspases-3 and -7, of several baicalein derivatives [S1 
(7-(allyloxy)-5,6-dihydroxy-2-phenyl-4H-chromen-4-one), S2 (6-dihydroxy-2-phenyl-7-
propoxy-4H-chromen-4-one) and S3 (5,6-dihydroxy-7-(isopentyloxy)-2-phenyl-4H-
chromen-4-one)] (Figure 17), which are analogues of compounds 1a and 2a.  
 
 
 
 
Figure 17 – Chemical structure of compounds S1, S2 and S3. 
 
 
The results obtained demonstrated that compounds S1-3 induced growth inhibition 
in yeast cells expressing procaspase-7 at 1-15µM (Figure 18A), without interfering with the 
growth of control yeast (data not shown). Interestingly, for the same concentration range, 
the effect of these compounds was less pronounced in yeast cells expressing procaspase-
3 (Figure 18B). 
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Figure 18 – Effect of compounds S1-S3 on the growth of yeast cells expressing procaspases-
3 or -7. Concentration-response curves for the effects of flavonoids S1-S3 on the growth of yeast 
cells expressing human (A) procaspase-7 or (B) procaspase-3, for 24 h treatment. The percentage 
of drug-induced growth inhibition was estimated considered 100% growth the number of CFU 
obtained with DMSO only. Data are mean ± SEM of six independent experiments; values significantly 
different from DMSO are indicated (*p=0.01, **p=0.001; unpaired). 
 
In addition, the GI25 values obtained from the concentration-response curves for the 
effects of 0.1-15 μM compounds S1-S3 and 0.1-50 μM PAC-1 (a known activator of 
procaspases-3 and -733) (data not shown), in yeast cells expressing procaspases-3 or -7,  
revealed that compounds S1 and S3 were significantly more potent than the positive control 
PAC-1, in yeast expressing procaspase-7 (Table 5). Despite the low GI25 value of 
compound S2 compared to PAC-1, in yeast expressing procaspase-7, the difference 
between both compounds is not statistically significant. More experiments must be 
performed in a future work to better clarify the potency of compound S2.   
 
Table 5 - GI25 values obtained for PAC-1 and flavonoids S1, S2 and S3. 
 
 
GI25 values correspond to the concentration that caused 25% growth inhibition of yeast cells expressing 
procaspases-3 or -7 after treatment with 0.1-15 μM flavonoids S1-S3, and 0.1-50 μM PAC-1 (positive control). 
Data are mean ± SEM of six independent experiments; values significantly different from PAC-1 are indicated 
(*p=0.01, **p=0.001; unpaired). ND – Not determined. 
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Interestingly, based on the GI25 values, in opposition to PAC-1, that showed to have 
activity in yeast cells expressing procaspases-3 or -7, compounds S1-S3 appear to be 
selective for procaspase-7 (Table 5). 
 
A similar yeast phenotypic assay was developed, by our group, for procaspase-6. 
The suitability of this yeast approach for the screening of activators of human procaspase-
6 was validated, in the present dissertation, by testing the effect of a known activator of 
procaspase-6 in yeast cells, M154150. As expected, for 1 and 5 µM, M1541 induced growth 
inhibition in yeast cells expressing procaspase-6 (Figure 19A), without interfere with the 
growth of control yeast (data not shown). These results demonstrated that as in human 
cells, M1541 was also able to activate procaspase-6 in yeast. 
This yeast screening approach was thereafter used to analyse the effect of 
compounds S2 and S3 on procaspase-6 activity. The results obtained showed that, for the 
concentration range tested (0.1-15 µM), both compounds did not interfere with the growth 
of yeast cells expressing procaspase-6 (Figure 19B). These results suggest that flavonoids 
S2 and S3 were not activators of procaspase-6. 
 
 
 
 
Figure 19 - Effect of compounds M1541, S2 and S3 on the growth of yeast cells expressing 
procaspase-6. Concentration-response curves for the effects of the (A) positive control M1541 and 
(B) flavonoids S2 and S3 on the growth of yeast cells expressing human procaspase-6 for 24 h 
treatment. The percentage of drug-induced growth inhibition was estimated considered 100% growth 
the number of CFU obtained with DMSO only. Data are mean ± SEM of six independent experiments; 
values significantly different from DMSO are indicated (*p=0.01, **p=0.001; unpaired).  
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3.2. PKC FAMILY PROTEINS 
 
In a previous work from our group a yeast targeted screening assay was developed 
to search for modulators of PKC family proteins74. Using this approach a diterpene 
compound (coleon U) was identified as a potent and selective activator of the novel PKC δ 
and ε isoforms74. In this way, this yeast screening approach was used to analyse the effect 
of a coleon U derivative (compound C4) on the activity of several PKC isoforms. The results 
obtained in the yeast model indicated that C4 was a potent and selective activator of PKC 
δ (unpublished results). Based on this finding, in the present dissertation, several assays 
were performing in human tumour cell lines in order to analyse the in vitro antitumor 
potential of C4. 
 
C4 INDUCES A CYTOTOXIC EFFECT ASSOCIATED WITH APOPTOSIS IN HUMAN 
TUMOUR CELLS  
 
The tumour cell growth-inhibitory potential of C4 was ascertained using the human 
colon adenocarcinoma HCT116 cell lines (Figure 20). The GI50 value obtained for C4 of 
0.63 µM, in HCT116 cells, after 48 h treatment, showed that C4 has a potent growth 
inhibitory effect in human tumour cells. Additionally, the results obtained in HCT116 cells 
showed that C4 was significantly more potent than the known activator of classical and 
novel PKCs (used as positive control77), PMA with a GI50 value of 6.5 µM (*p<0.05) (Figure 
20A). 
Moreover, it was verified that the growth-inhibitory effect of compound C4, at the 
GI50 concentration, was not associated with cell cycle arrest (Figure 20B). Whereas, the 
growth-inhibitory effect of PMA, at the GI50 concentration, demonstrated to be associated 
with the induction of S-phase cell cycle arrest (Figure 20B). It was also observed that the 
growth-inhibitory effects of both PMA and C4, at the GI50 concentrations, were associated 
with the induction of late apoptosis (Figure 20C). By western blot analysis, it was verified 
that the growth-inhibitory effect induced by C4 led to the induction o PARP cleavage, a 
product of caspase-3 activation, in HCT116 tumour cells (Figure 20D).  
Altogether, these results showed that C4 has a potent in vitro tumour growth-
inhibitory activity associated with the induction of apoptosis.  
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Figure 20 – C4 induces a potent growth-inhibitory effect associated with apoptosis induction, 
in human colon adenocarcinoma HCT116 tumour cells. (A) The GI50 concentration of PMA 
(positive control) and C4 was determined in HCT116 cells, after 48 h treatment, using the SRB assay. 
Data are mean ± S.E.M. of three independent experiments; values significantly different from PMA 
(*p<0.05) are indicated. (B) 0.63 µM C4 does not induce cell cycle arrest in HCT116 cells, after 24 h 
treatment. Cell cycle phases were analyzed by flow cytometry using PI staining; data are mean ± 
S.E.M. of three independent experiments. (C) 0.63 µM C4 induces late apoptosis in HCT116 cells, 
after 24 h treatment. Apoptosis was analyzed by flow cytometry using FITC-Annexin V and PI; data 
are mean ± S.E.M. of three independent experiments. (D) 0.63 µM C4 leads to PARP cleavage in 
HCT116 cells, after 24 h treatments. Immunoblots represent one of three independent experiments; 
GAPDH was used as loading control. In B and C, values significantly different from DMSO only: 
*p<0.05, **p<0.01. 
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Cancer is a major public health problem worldwide and the number of new cases is 
expected to rise significantly in the next decades. An additional concern is the increase of 
the resistance to the chemotherapy associated with many cancers.   
Apoptosis is a crucial cellular process for the maintenance of tissue homeostasis in 
multicellular organisms. In fact, the mechanisms of apoptosis are highly complex and 
sophisticated, involving an energy-dependent cascade of molecular events. The 
deregulation of this process has been implicated in carcinogenesis [reviewed in4]. In this 
way, in the last years, the search for new anticancer therapies that selectively modulate 
proteins involved in the apoptotic process has been the focus of an intense research in 
order to overcome the resistance and to trigger tumour cells into apoptosis.  
The yeast cell model has emerged as a powerful tool to study the biology and 
pharmacology of cancer-related proteins. In fact, yeast-based screening assays have 
already proven to be widely effective in the first-line screening of genetic and chemical 
libraries, leading to the successful identification of promising pharmacological modulators 
of human proteins involved in apoptosis, such as caspases and PKCs [reviewed in56, 60, 76].  
Hence, with the present dissertation it was intended to use the yeast cell system to 
discover new small molecule modulators of pro-apoptotic proteins, with improved 
pharmacological properties. In fact, in the present work, promising modulators of caspases 
activity were identified. Additionally, the in vitro antitumor potential of a selective activator 
of PKCδidentified in yeast was confirmed.  
 
4.1. IDENTIFICATION OF FLAVONOIDS S2 AND S3 AS POTENTIAL SELECTIVE 
ACTIVATORS OF CASPASE-7  
 
At the core of the execution phase of apoptosis are the executioner caspases-3, -6 
and -7. Like most proteases, these caspases are stored as procaspases that once 
activated, cleave a large set of substrates, ultimately resulting in the characteristic 
morphological and biochemical hallmarks of apoptosis. The reduced expression of pro-
apoptotic caspases has been reported in manifold cancers and specific inactivating 
mutations in many tumour types and stages of malignant transformation [reviewed in21]. 
Indeed, the search for activators of these proteins can be considered as a novel strategy in 
cancer therapy by selective induction of apoptosis in cancer cells [reviewed in21, 108]. Despite 
that, to date, only few small molecule caspase activators have been reported. In fact, it has 
been shown that some of them have low antitumor activity and high toxicity49a. Therefore, 
these considerations led to intensive efforts to discover new executioner procaspase 
activators. 
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Since flavonoids and their synthetic analogues have revealed therapeutic potential 
as anticancer agents, inhibiting distinct stages of the carcinogenesis process [reviewed 
in78a], it is reasonable to consider this scaffold as a valuable tool for the development of new 
and more potent pro-apoptotic agents that could be helpful in the therapy against cancer. 
In fact, in several human tumour cells, it was demonstrated that the flavonoid baicalein 
induced a cell growth inhibitory effect associated with apoptotic cell death through a 
caspase-dependent manner109. Additionally, in a previous work from our group, two new 
potential small molecule activators of caspase-7, without interfering with the activity of 
caspase-3, were identified: the prenylated flavonoids 1a (5,6-dihydroxy-7-prenyloxyflavone) 
and 2a (3-hydroxy-7-geranyloxyflavone). These compounds were the first identified 
caspase activators with a flavonoid scaffold. In fact, these flavonoids showed to be potent 
growth inhibitors of the breast cancer (MCF-7) and leukaemia (HL-60) human tumour 
cells99, by an increase of caspase-7 activity and procaspase-7 cleavage. This data 
demonstrated that prenylated flavonoids would be a promising scaffold to search for 
activators of executioner caspases key elements of the apoptotic process. Based on these 
previous results, derivatives of compounds 1a and 2a were synthesised [S1 (7-(allyloxy)-
5,6-dihydroxy-2-phenyl-4H-chromen-4-one), S2 (6-dihydroxy-2-phenyl-7-propoxy-4H-
chromen-4-one) and S3 (5,6-dihydroxy-7-(isopentyloxy)-2-phenyl-4H-chromen-4-one) 
(Figure 17)], and their activity as activators of caspases-3, -6 and -7 was evaluated using 
the previous developed yeast-based screening assay99. 
With this approach, the flavonoids S2 and S3, were identified as potential selective 
activators of procaspase-7. In fact, compounds S2 and S3 showed to be much less potent 
on procaspases-3 and -6 when compared to procaspase-7. Further assays are underway 
in order to analyse the impact of compound S1 on the activity of procaspase-6 expressed 
in yeast. Despite this, as S2 and S3, compound S1 showed to be ineffective on procaspase-
3 and exhibited a similar potency to S2 as activator of procaspase-7.  
Additionally, the results revealed that S1 and S3 were significantly more potent 
activators of procaspase-7 than the positive control PAC-1. In addition, in opposition to 
PAC-1 that activates both procaspase-3 and -7, S1, S2 and S3 appear to be selective for 
procaspase-7.   
Together, with the present dissertation three potential activators of caspase-7 (S1, 
S2 and S3) were identified. From these three small molecules, S3 may be selected to be 
further explored in human tumour cells, since reveals to be a selective and potent activator 
of procaspase-7. Since S3 have an isopentyl substituent, in a future work it would be 
interested to test if this substituent is a structural requirement for the selectivity of these 
compounds for procaspase-7. Promising pharmacological applications can be therefore 
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envisaged for these compounds, not only as probes in the study of caspases pathway, but 
also as anticancer agents. In fact, these flavonoids may represent an alternative strategy 
for personalized cancer treatment, namely against tumours without caspase-3 (e.g., breast 
adenocarcinoma) or with high levels of caspase-7 (e.g., prostate cancer). 
 
4.2. COMPOUND C4 HAS A POTENT IN VITRO TUMOUR GROWTH INHIBITORY 
EFFECT ASSOCIATED WITH APOPTOSIS INDUCTION 
PKC is a family of serine/threonine kinases that exert an important role in the 
carcinogenesis process. This family is composed by several isoforms considered crucial 
regulators of cell death and proliferation [reviewed in54b]. Once individual PKC isoforms can 
exert either similar or opposite effects in cell proliferation and death, an individual 
modulation of PKC isoforms effects is highly required. However, the current PKC 
modulators that have been currently described are relatively non-specific. Thus, the 
identification of PKC isoform-selective modulators has deserved great attention in drug 
discovery. 
Particularly, the PKCδ been implicated in cell death, in the regulation of both intrinsic 
and extrinsic apoptotic pathways [reviewed in64]. The loss of PKCδ expression has been 
reported in some cancer types69-71. As such, the search for selective activators of this 
isoform is an appealing strategy in cancer therapy. 
Due to the high complexity of the mammalian PKC family, particularly the 
coexistence of several PKC isoforms in the same cell, yeast-based assays were previous 
developed by our group to study the biology and pharmacology of each isoform of the PKC 
family [reviewed in56, 60, 76]. In this way, using the previous developed yeast target directed 
screening assay to search for modulators of PKC isoforms74 C4 was identified as a 
promising potent and selective activator of PKCδ. Based on this, in the present dissertation 
the in vitro antitumor potential of C4 was addressed in the human colon adenocarcinoma 
tumour cells HCT116. Compound C4 was able to decrease the proliferation of HCT116 
tumour cells, being more potent than the known activator of the PKC family, PMA. In fact, 
contrary to PMA, the antiproliferative effect of C4, in tumour cells, was not associated with 
a cytostatic effect (cell cycle arrest), but instead with the induction of apoptosis only.  
Altogether, compound C4 shows to be a promising compound to be further explore 
as potential anticancer agent. 
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4.3. FUTURE PROSPECTS 
 
The results obtained in this dissertation may open the way to further works. Particularly, 
it would be interesting to: 
i) Validate the molecular mechanism of action, in human tumour cells, of 
compound S3; 
ii) Analyse the activity of the alkylated flavonoid S1 on yeast cells expressing 
procaspase-6; 
iii) Evaluate the activity of new synthesized derivatives of the alkylated flavonoids 
S1, S2 and S3 on procaspases-3, -6 and -7 activities, particularly of derivatives 
without the isopentyl substituent;   
iv) Validate the molecular mechanism of action of compound C4 in human tumour 
cells, and evaluate it antitumor properties in vivo. 
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Accumulating evidence has shown the crucial role of the caspase family in both 
initiation and regulation of apoptosis [1]. Caspases-3 and -7 are at the core of the execution 
phase of apoptosis. Like most proteases, these “executioner” caspases are stored as 
procaspases that once activated by proteolysis cleave a large set of substrates, ultimately 
resulting in the characteristic morphological and biochemical hallmarks of apoptosis. 
Therefore, the search for activators of these procaspases has deserved particular attention 
in the field of anticancer drug discovery [2,3]. Nevertheless, to date, only few small-molecule 
caspase activators have been reported [2, 4]. A previous study from our group have 
reported the identification of two potential activators of caspase: 7, 5,6-dihydroxy-7-
prenyloxyflavone (1a) and 3-hydroxy-7-geranyloxyflavone (2a) by using a yeast target-
based screening assays, based on the heterologous expression of these human proteins in 
Saccharomyces cerevisiae [5]. These results led us to the present project under the thesis 
for Masters in Pharmaceutical Chemistry aiming to discover new caspases -3 and 7 
activators. In the present work, several derivatives of compounds 1a and 2a will be 
synthesised and the activity as activators of caspases-3 and -7 will be evaluated using the 
yeast approach followed by validation of the molecular mechanism of action in human tumor 
cells. With this work it is intended to identify new activators of caspases-3 and -7 with 
improved pharmacological activities. 
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Caspases are a family of proteases with a crucial role in the initiation and regulation 
of apoptosis [1]. At the core of the execution phase of apoptosis are the executioner 
caspases 3 and 7. Like most proteases, these caspases are stored as procaspases that 
once activated by proteolysis, cleave a large set of substrates, ultimately resulting in the 
characteristic morphological and biochemical hallmarks of apoptosis. Therefore, the search 
for activators of these procaspases has deserved particular attention in the field of 
anticancer drug discovery [1]. Nevertheless, to date, only few small molecule caspase 
activators have been reported [1]. 
In a previous work from our group, the use of a yeast screening assay, based on the 
heterologous expression of human caspases 3 or 7 in the yeast Saccharomyces cerevisiae, 
led us to the identification of two activators of caspase 7: 5,6-dihydroxy-7-prenyloxyflavone 
(1a) and 3-hydroxy-7-geranyloxyflavone (2a) [2]. These results prompted us to the present 
work aiming to discover new activators of caspases 3 and 7. For that, several analogues of 
compounds 1a and 2a were synthesized, and their activities on caspases 3 and 7 were 
evaluated, using the previously developed yeast-based screening assay [2]. Potential 
activators of caspases 3 and/or 7 were therefore identified with improved pharmacological 
properties compared to their starting analogues. Further work is underway to confirm their 
molecular mechanisms of action in human tumor cells. 
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The search for new anticancer therapies has been focused on devising ways to 
overcome resistance and to trigger apoptosis in tumour cells [1]. Caspases are a family of 
proteases with a crucial role in apoptosis [2]. At the core of the execution phase of apoptosis 
are the executioner caspases-3 and -7. These caspases are stored as procaspases that 
once activated by proteolysis cleave a large set of substrates, ultimately resulting in the 
morphological and biochemical hallmarks of apoptosis. Thus, the search for procaspase 
activators has deserved particular attention in anticancer drug discovery [2]. Yet, to date, 
few small-molecule caspase activators have been reported [3,4]. Our previous study 
reported the identification of two potential activators of caspase-7: 5,6-dihydroxy-7-
prenyloxyflavone (1a) and 3-hydroxy-7-geranyloxyflavone (2a) using a yeast screening 
assay, based on the heterologous expression of these human proteins in Saccharomyces 
cerevisiae [5]. These results prompted us to discover new activators of caspases-3 and -7. 
For that, several analogues of compounds 1a and 2a were synthesized, and their activities 
on these caspases were evaluated, using the developed yeast assay [5]. Potential selective 
activators of caspase-7 were identified with improved pharmacological properties compared 
to their starting analogues. Further work is underway to confirm their molecular mechanisms 
in human tumor cells. 
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